Tags : Bladder Cancer

Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on

Shots: Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M […]Read More

Roche Reports Results of Tecentriq in P-III IMvigor130 Study for

Shots: The P-III IMvigor130 study involves assessing of Tecentriq + platinum-based CT vs platinum based-CT as monothx. in 1213 patients with metastatic urothelial carcinoma (mUC) prior not treated with systemic therapy The P-III IMvigor130 study resulted in meeting its 1EPs of PFS with the reduction in the risk of disease worsening or death, improved OS […]Read More

SDSC and Moores Cancer Center Collaboratively Work with CureMatch to

Shots: The machine learning model utilizes MLP (multi-layer perceptron) software, providing a non-invasive diagnostic option, analyzes a patient’s metabolites and their chemical descriptors, generating AI models to detect and identify the stage of cancer The focus of the research is to minimize the number of cancer cases & to create an ease for patients to […]Read More